Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Stoke Therapeutics (NASDAQ:STOK) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38, Zacks reports. The company had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Stoke Therapeutics Stock Down 3.3 %

Shares of STOK traded down $0.30 on Wednesday, reaching $8.58. The stock had a trading volume of 72,240 shares, compared to its average volume of 826,195. The firm has a market capitalization of $454.19 million, a PE ratio of -4.05 and a beta of 0.99. Stoke Therapeutics has a twelve month low of $5.60 and a twelve month high of $17.58. The firm has a 50-day moving average of $9.52 and a 200 day moving average of $11.54.

Analyst Ratings Changes

A number of brokerages have issued reports on STOK. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.